The agreement with Pfizer, announced Wednesday morning by the company and the Department of Health and Human Services, is the largest to date for Operation Warp Speed. The federal government announced this month that it would provide $1.6 billion to Maryland-based Novavax to accelerate the development of a coronavirus vaccine. Pfizer and BioNTech expressed not only their cooperation, but also interest in a possible supply of the COVAX facility, a mechanism put in place by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovation (CEPI) and the World Health Organization (WHO) to enable governments to access a large portfolio of cable vaccines with a range of technology platforms early. , produced by several manufacturers around the world. Major vaccine studies, scheduled to begin this month, will each include 30,000 people, some receiving placebo shots. The Food and Drug Administration has said that a vaccine against coronavirus should protect 50% of those who receive it to be considered effective. NEW YORK – MAINZ, Germany— (BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S.

administration`s goal of Operation Warp Speed to begin delivering 300 million doses of COVID-19 vaccines in 2021. As part of the agreement, the U.S. government receives 100 million doses of BNT162, the candidate for the coVID-19 vaccine jointly developed by Pfizer and BioNTech, after Pfizer has successfully obtained the approval or approval or emergency approval of the U.S. Food and Drug Administration (FDA). This press release contains “forward-looking statements” from BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may contain information about BioNTech`s efforts to combat COVID-19, but not limited to this: the opening date of clinical trials with BNT162 and the likely publication of data from these clinical trials; The date of authorization or authorization for the use of an emergency physician; The potential for additional supply agreements with other legal systems or the COVAX facility; The potential safety and effectiveness of BNT162; BioNTech and Pfizer`s cooperation in developing a potential COVID-19 vaccine; and BioNTech`s ability to provide quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021. All forward-looking statements contained in this press release are based on BioNTech`s current expectations and beliefs in future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and negatively from the results presented or implied in such forward-looking statements. These risks and uncertainties include, among other things, competition for the creation of a vaccine against COVID-19; The ability to achieve comparable clinical outcomes in larger and more diverse clinical trials; The ability to effectively develop our production capacity; and other potential difficulties.

An explanation of these risks and other uncertainties can be contained in BioNTech`s Management Report on Form 20-F, submitted to the SEC on March 31, 2020 and available on the SEC`s website at www.sec.gov. All information contained in this press release refers to the date of publication and BioNTech undertakes no commitment to update this information, unless required by law. Pharmaceutical giant Pfizer and German biotech company BioNTech will provide the federal government with 100 million doses of their coronavirus vaccine as part of a $1.95 billion deal announced Wednesday, the government`s biggest investment to date in a vaccine that has proven effective.